Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer-Reference-Cited by-同舟云学术

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Published:2012-07-20 Issue:4 Volume:14 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Byrski Tomasz,Dent Rebecca,Blecharz Pawel,Foszczynska-Kloda Malgorzata,Gronwald Jacek,Huzarski Tomasz,Cybulski Cezary,Marczyk Elzbieta,Chrzan Robert,Eisen Andrea,Lubinski Jan,Narod Steven A

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3231.pdf

Reference24 articles.

1. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD: A significant response to neo-adjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002, 39: 608-610. 10.1136/jmg.39.8.608.

2. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J: Response to neoadjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008, 108: 289-296. 10.1007/s10549-007-9600-1.

3. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009, 361: 123-134. 10.1056/NEJMoa0900212.

4. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT: BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat. 1997, 44: 275-277. 10.1023/A:1005830230664.

5. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storger-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

2. Mechanistic insights into cisplatin response in breast tumors: Molecular determinants and drug/nanotechnology-based therapeutic opportunities;Mutation Research - Reviews in Mutation Research;2024-07

3. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05

4. Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer;Cancer Chemotherapy and Pharmacology;2024-04-23

5. Real-world data in patients with BRCA mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors;ecancermedicalscience;2023-11-21